In the Spotlight...
Perioperative pembrolizumab in locally advanced CSCC- A prospective phase 2 clinical trial
Relatlimab plus nivolumab versus nivolumab for advanced melanoma: 5-year survival and biomarker analyses of the phase 3 RELATIVITY-047 trial
A genome‑wide screen in E. coli reveals metabolic adaptations that enhance intratumoral fitness and bacterial cancer therapy efficacy
DC vaccine loaded with Bacteroides fragilis elicits functional cross-reactivity and enhances anti-PD-1 immunotherapy
Previous Digests
Ovarian cancer care gets personal in a phase 1 vaccine trial
November 4, 2026
Epithelial ovarian cancers (OCs) are difficult to treat and rarely benefit from immunotherapy, likely due to poor priming. However, cancers with similarly low tumor mutation burden (TMB), have benefited from cancer vaccines. In a recent phase 1 clinical trial...
Not Cullin it quits: removing CRL5 sustains T cell function in tumors
October 28, 2026
The lack of persistence after adoptive T cell therapies due to T cells becoming dysfunctional under chronic exposure to tumor antigens limits their efficacy. Two recent back-to-back publications by Bachl et al. and Saco et al. in Cancer Immunology...
New PrimeCAR protocol delivers improved CAR T cells in less time
October 21, 2026
CAR T cells are a powerful treatment option for certain cancers, but their use can be limited by long manufacturing times and severe toxicities. In order to overcome these hurdles, Yang and Li et al. developed a new CAR...
Watch ACIR in action
In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.
Watch the 3-minute video explaining ACIR's mission and goal:
In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.
Watch the 6-minute segment on the story behind your favorite digest here:
About ACIR
ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.
Ute Burkhardt
Ed Fritsch
Lauren Hitchings
Gaëlle Llambi
Maartje Wouters
Alex Najibi
Katherine J. Turner
Stan Wolf
Paula Hochman
Shishir Pant
Nathan Suek
Morgan Janes
TESTIMONIALS
I'm a big fan of ACIR. I enjoy their weekly newsletters with clear, concise, and insightful summaries, complemented by excellent images. I've even used the images in some of my presentations to explain complex cancer immunotherapy findings. In our rapidly evolving field, their reliable and well-curated updates are invaluable.
Richard W. Vague Professor in Immunotherapy; Professor of PL&M; Director, Center for Cellular Immunotherapies; Director, Parker Institute for Cancer Immunotherapy; University of Pennsylvania Perelman School of Medicine. (Supporter since 2025).
Current Sponsors
